ClinicalTrials.gg
RecruitingNCT05409833CarPoSUpdated Oct 19, 2023

Systemic Transthyretin Amyloidosis: Carpal Tunnel Syndrome in a Portuguese Population

An observational study in Transthyretin Amyloidosis and Carpal Tunnel Syndrome, sponsored by Universidade do Porto. Recruiting at 2 sites in Portugal. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2023-10-19.

Sponsored by Universidade do Porto · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2020; still recruiting 6 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
100
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in Portugal — 7 open to participants now, 9 under way, 4 of them phase 3. Amyloidosis, Hereditary, Transthyretin-Related · Portugal.

Started
2020
with 1 other
Observational
5 of 15
3 open now
Registered
10th of 15
by date
Lead sponsor
1 of 15
Universidade do Porto

Among the 15 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in Portugal, this one is one of 2 that started in 2020, is one of 5 observational ones, and was the 10th registered.

Amyloidosis, Hereditary, Transthyretin-Related

82 studies on the registry are indexed under Amyloidosis, Hereditary, Transthyretin-Related; 28 are open to participants now.

Browse Amyloidosis, Hereditary, Transthyretin-Related studies →

Open to participants now

7 of the 15 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in Portugal are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →

Who these studies take

Of the 22 Amyloidosis, Hereditary, Transthyretin-Related studies recruiting now, 15 (68%) set no upper age limit and 1 (5%) stops at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in Portugal, or all of them as a file.
02

Study summary

Systemic transthyretin amyloidosis is an aging-related disorder. It is usually associated with cardiac disease but also extends to other organs. Recent studies found that idiopathic carpal tunnel syndrome patients may have amyloid deposition in tenosynovial tissue. The main aims of this project are the characterization of the association between idiopathic carpal tunnel syndrome and transthyretin amyloidosis and its evaluation as a predictive factor of cardiac amyloidosis

03

Conditions studied

  • Transthyretin Amyloidosis
  • Carpal Tunnel Syndrome
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with ≥60 years old submitted to hand surgery

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

. Patients aged ≥ 60 years old with symptomatic idiopathic carpal tunnel syndrome or other hand surgery indications.

Exclusion criteria

Exclusion Criteria:

. Diabetes mellitus, hypothyroidism, hemodialysis, rheumatoid arthritis, and other inflammatory arthropathies, multiple myeloma, gout, chondrocalcinosis, Colles fracture, space-occupying lesions, and infectious synovitis.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Group 1

    Patients aged ≥ 60 years old with symptomatic carpal tunnel syndrome submitted to surgery

    Diagnostic Test: Synovial biopsy and Cardiac scintigraphy with [99mTc]Tc-DPD

  • Group 2

    Patients aged ≥ 60 years old without symptomatic carpal tunnel syndrome submitted to hand surgery

    Diagnostic Test: Synovial biopsy and Cardiac scintigraphy with [99mTc]Tc-DPD

Interventions

  • Diagnostic testSynovial biopsy and Cardiac scintigraphy with [99mTc]Tc-DPD

    Congo red and Immunohistochemical analysis and/or Mass spectrometry analysis

06

What researchers measure

Primary outcomes

  1. Frequency of transthyretin amyloidosis in synovial in patients with ≥60 years old

    Number of patients with transthyretin amyloidosis in synovial in relation to total number of patients submitted to hand surgery

    Time frame: 24 months

Secondary outcomes

  1. Association between synovial transthyretin amyloidosis with carpal tunnel syndrome

    Comparison between group 1 and 2

    Time frame: 24 months

  2. Association between idiopathic carpal tunnel syndrome with cardiac transthyretin amyloidosis

    Comparison between group 1 and 2

    Time frame: 24 months

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2020 (actual). Primary completion is estimated for Jun 2024, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2022
First posted
Jun 8, 2022
StartActual
Jun 1, 2020
Primary completionEst.
Jun 1, 2024
CompletionEst.
Jun 1, 2025
Last update
Oct 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05409833
Collaborators
Centro Hospitalar De São João, E.P.E., Centro de Investigação em Tecnologias e Serviços de Saúde, Rede de Investigação em Saúde
Responsible party
Sponsor
First posted
Jun 8, 2022
Start date
Jun 1, 2020
Primary completion
Jun 1, 2024 (estimated)
Completion
Jun 1, 2025 (estimated)
Last update
Oct 19, 2023

Study contacts

Elisabete Martins, MD, PhD
Contact
ebernardes@med.up.pt
(+351) 965913480
Janete Santos, PhD
Contact
investigaclinica@med.up.pt
(+351) 225 513 600
Elisabete Martins, MD, PhD
principal investigator · Universidade do Porto

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion